Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr;41(3):163-169.
doi: 10.1097/MPH.0000000000001369.

Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma

Julie Voeller  1 , Paul M Sondel  1   2
Affiliations
Review

Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma

Julie Voeller et al. J Pediatr Hematol Oncol. 2019 Apr.

Abstract

Neuroblastoma (NBL) is the most common extracranial solid tumor in pediatrics, yet overall survival is poor for high-risk cases. Immunotherapy regimens using a tumor-selective antidisialoganglioside (anti-GD2) monoclonal antibody (mAb) have been studied for several decades now, but have only recently been incorporated into standard of care treatment for patients with high-risk NBL with clear benefit. Here we review a brief history of anti-GD2-based immunotherapy, current areas of neuroblastoma research targeting GD2, and potential diagnostic and therapeutic uses targeting GD2.

PubMed Disclaimer

References

    1. Couzin-Frankel J Breakthrough of the year 2013: Cancer immunotherapy. Science. 2013. December 20;342(6165):1432–3. - PubMed
    1. Yu AL, Gilman AL, Ozkaynak MF, et al.; Children’s Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324–34. - PMC - PubMed
    1. Schulz G, Cheresh DA, Varki NM, et al. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res. 1984. December;44(12 Pt 1):5914–5920. - PubMed
    1. Kramer K, Gerald WL, Kushner BH, et al. Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma. Clin Cancer Res. 1998. September;4(9):2135–2139. - PubMed
    1. Yang RK, Sondel PM. Anti-GD2 Strategy in the Treatment of Neuroblastoma. Drugs of the future. 2010;35(8):665-. - PMC - PubMed

Publication types